% | $
Quotes you view appear here for quick access.

ЕЛН Message Board

bocamp1 350 posts  |  Last Activity: 2 hours 37 minutes ago Member since: Oct 13, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • No one except you,donk, in your not so hidden short agenda, is looking for a 350,000 dollar finance deal. What good would that do? If they needed small short term money like that, they would just do another inside convert deal.
    They will do a deal at some point. But. you have no clue as to when or at what price.

    Gtree trading is a great tell, for those who really are long time longs. That stock had a usual bout of profit taking to take it off the highs (after 600%+gains) and now is rallying on good volume. Now, are they at that market cap because they just bought some preclinical drug that will compete against juno, kite, bmy.....? Or might they be seeing some early data on late stage P3 trials in NK and dry eye; a market a little less crowded than immuno-oncology area.

  • Reply to

    Any offering won't be huge

    by snogreen Feb 25, 2016 12:39 PM
    bocamp1 bocamp1 Feb 25, 2016 1:57 PM Flag

    Dont forget NK. According to Ora, the drug for this orphan indication has a market patient population of 50k in US and 50k in EU. There is nothing on the market for this.
    The success of this trial will once again, be very much up to Ora matching the drug to the patient and severity of condition.. Are they going to treat stage 1 only? Or the harder to treat stage 2 and 3? It makes sense to just treat the stage 1, as that is by far the largest market and the easiest to treat. The bet here in NK and dry eye, is that Ora is as good as everyone seems to think. If so, huge success lies ahead.

  • Who can blame him? He has had to defend the indefensible; the corrupt world of Ma, Castle and Leiberman.
    More selling again today.
    We should all find out soon, Q report, if Netwolves was the great buy Ma and Castle presented. Watch that cash balance.

  • Reply to

    Eye NK trial. what stages?

    by snogreen Feb 25, 2016 2:26 PM
    bocamp1 bocamp1 Feb 25, 2016 2:38 PM Flag

    Well, its hard to say. Its difficult to get patients, so maybe they take 2 or 3 also.(stage 2's better) But, according to Ora, the market is much smaller for 2 and 3; only about 10k in EU and US.
    RGRX has a history of going for the tougher patients. But, we did pretty well in the earlier small trial in the stage 3's. So, maybe Ora has confidence here.
    I do think Ora and more importantly the Koreans know already if first patients are seeing a positive result as you would expect no result from placebo here; unlike dry eye. This may be one of the reasons for gtree's stock recent performance. And as you say, the Koreans dont have the SEC looking over their shoulder like they do here.

  • look very good

  • Reply to

    Crazy Quiet Here

    by atczero14 Feb 25, 2016 1:53 PM
    bocamp1 bocamp1 Feb 25, 2016 4:36 PM Flag

    Big volume in the march 40 calls; someone bought over 2000 contracts in one trade at .65. They closed today at 1.3. Whats up?

  • Except shareholders. What a bunch of nonsense. They meet goals? According to who?
    These guys should all be fired. Amgn should buy and kick their butts to the street.

  • Why do they get rewarded for failure? Only on wall st. Look at this years stock performance. Does this company give a rats butt for shareholders? NO

  • Reply to

    Did They Meet Endpoint in ALS Trial....NO

    by bocamp1 Feb 25, 2016 4:58 PM
    bocamp1 bocamp1 Feb 25, 2016 5:59 PM Flag

    Really? You have no clue what i know. What i know is that cytk management data mine their nothing results to proclaim success. They offer little to nothing to this horrilbe affliction. They offer a little more than 1 extra breath of life; who needs it? They build up hope and then offer NOTHING. That is reprehensible
    No drug would meet endpoint? But, they claim 90% success based on pay and bonus. Are ALS victims so fortunate.? Are shareholders? No, only worthless management.
    Management tried and you are forgiving. Isnt that special. I have no position but just cant stand a team taking shareholders money, building up patients expectations, and then claiming success . You sleep well at night, you must work for this lying company.
    The only hope for shareholders is amgn and the heart indication. The ALS drug should be givin up for dead, but they might not get their bonuses then.

  • Reply to

    Did They Meet Endpoint in ALS Trial....NO

    by bocamp1 Feb 25, 2016 4:58 PM
    bocamp1 bocamp1 Feb 25, 2016 6:13 PM Flag

    I will buy here for heart indication, not for als failure and slight of hand. You think you have done great dd, share price says differently. And thats all that counts. ALS will never be a winner here for company, shareholders or patients; only fat cat mangement.

    Good luck. I feel you pain on rlyp; I cant believe the price of that one. Such is bio investing

  • bocamp1 bocamp1 Feb 26, 2016 11:54 AM Flag

    "f they sold in May, it would be before trial is completed..." Completely wrong and a stupid comment

    I guess you have learned korean lately. You were not sure of translation before. But, all clear to you now?.
    There is no way koreans get any real value from JV BEFORE results. Its more likely the language in the korean PR is saying that they will leave actual FDA approval up to another entity(sell JV). They will have results by May so this makes perfect sense; sell after positive results on dry eye. So, since JV is not sellable before results, and May is their sell date, results from a time and success standpoint are known to them. RGRX Shareholders should take this, along with gtree stock price, as a very postive sign. No pharma will buy before positive results
    And the Koreans and Ora are running trials. They do not, nor do they have to, share all with RGRX management. You keep saying both parties are equal in terms of trial knowledge. You do not know this. The Koreans run the show and JJ will get interim results and final JV sale terms when the koreans see fit. And you can bet that he has final approval and would no entertain a low ball, pre trial result sale.

  • bocamp1 bocamp1 Feb 26, 2016 12:47 PM Flag

    How many drugs get sold between P2 and P3 for example...???

    I have never seen a buyout for a single drug done weeks before final trial results. And the reason for that is obvious, except to you i guess. If you have an example, please tell us. And i am not talking about a buyout of an entire biotech that has additional pipeline besides one targeted drug.
    Your lack of knowledge in this biotech space should cause all to question (ignore) your posts.

  • Reply to

    Reseller is Losing It

    by bocamp1 Feb 25, 2016 2:19 PM
    bocamp1 bocamp1 Feb 26, 2016 6:21 PM Flag

    You are quite the psychologist, reseller. You are a newbie compared to some major investors here. I could give a rats butt about your opinion, as your many previous posts have shown an incredible rate of inaccuracies. In fact, i dont think a thing you have ever said about price action or management credibility has been correct; now thats quite the record.
    I made some serious money(as smalls did) when stock was stuck at a nickel(i was the mm in effect, and bought almost everyday for over a year) for what seemed like forever. So, no matter what happens now, i will always be ahead of the game. I i do thank Ma for the original GE deal that gave me my returns. My only emotion of late is total disappointment in Ma;s failure to not execute the original business plan. He gave up and took the Castle. Leiberman path. He was talked into the "investment banker" bs. And in so doing, he has tainted whatever legacy he might have had here. And, he has lost all benefit of the doubt. He is just another greedy, overpaid, non performer now.............with poor language skills...................

  • Reply to

    Did They Meet Endpoint in ALS Trial....NO

    by bocamp1 Feb 25, 2016 4:58 PM
    bocamp1 bocamp1 Feb 29, 2016 6:11 PM Flag

    This drug does little to help ALS patients and provides nothing but a false hope.: another month of struggle?
    And many primary endpoints are subjective. Just look at dry eye trials at shire.

    Anyway my main point here was that management has delivered little to shareholders and yet they feel entilted to bonus and big salaries? Give me a break. I am so sick of little bio's run by managements that are not aligned with the owners.
    Amgn is the only hope for this company.

  • bought 3000 april 22.2 @ 4
    Sold 6000 april 35 calls @ .75

  • Reply to

    Why and who?

    by gkas711 Mar 2, 2016 1:53 PM
    bocamp1 bocamp1 Mar 2, 2016 4:26 PM Flag

    Below is the most convoluted logic i have ever seen

    I'm actually GLAD that we are in low 40 cents. because if trial flops, we only have a few dimes to lose. Other stocks that get "noticed and hyped" run way up on Phase 3 hoped for news. But if it fails, you have a LOT lower to go and lose. Imagine if RGRX was hyped and all knew about it.....and anticipation of Phs 3 got us to $1.50 or $2.00. if the trial flopped and most of us have SIX figures of numbers of shares, a drop of $1.50 would be a killer. But a drop of a few dimes from 40 cents? That won't hurt as bad. And if trial wins, it will be MUCh sweeter to start from 40 cents and skyrocket!. .

  • Reply to

    Why and who?

    by gkas711 Mar 2, 2016 1:53 PM
    bocamp1 bocamp1 Mar 2, 2016 4:59 PM Flag

    Sno, there obviously isnt much to say as we wait for results. You should just be quiet. That was just an idiot post spoken by someone who could only own very few shares...........good luck

  • Reply to

    Why and who?

    by gkas711 Mar 2, 2016 1:53 PM
    bocamp1 bocamp1 Mar 2, 2016 5:49 PM Flag

    I was not questioning your ownership. My posts were directed at sno and his silly satisfaction with a 40 cent price vs a 2 dollar price....just amazing.

  • Reply to

    Where is our Press Release?

    by bigboyedd Mar 3, 2016 10:43 AM
    bocamp1 bocamp1 Mar 3, 2016 11:08 AM Flag

    Price action in Gtree yesterday was very telling. Stock had a little profit taking at the opening but then finished on the HOD. Are they seeing good data?

  • bocamp1 by bocamp1 Mar 3, 2016 3:20 PM Flag

    Anyone selling on that PR is nuts. Trial on time and 1000's of data points have to be analysed. Will it take till June for any data to come out? Not likely. JJ has hinted we will see data way before June. All you have to do is watch gtree stock. Koreans are seeing data and stock is reacting accordingly. I would expect a 1 miilion+ day in gtree with 10% or better gains there to be the real tell.
    Also clear, as i said, Koreans do things on their own. If JJ had this pr(if koreans had told him ahead of time) he would have issued a PR. Between the language barrier, distance, and general Asian business attitude of "only we matter," I would expect trial results to be announced by koreans before rgrx even gets details. IMHO...........No matter, jj has final say on any deal resulting from positive results.

    As usual, nite takes advantage of this unknown stock called rgrx. They can push around price as they wish. In the end( very soon), it will not matter. Watch gtree for the real deal.

18.12+0.2000(+1.12%)Dec 18 3:59 PMEST